Berman Capital Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Berman Capital Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1K	Buy	+3	New	+$1.07K	﹤0.01%	1802

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Berman Capital Advisors's ATRA Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Atara Biotherapeutics (ATRA) in Q3 2021: 3 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1802 among its holdings.

140 funds tracked by Wall St. Rank hold ATRA as of Q3 2021.

Berman Capital Advisors held 3 shares of Atara Biotherapeutics worth $1K as of Q3 2021.
Atara Biotherapeutics was a new Berman Capital Advisors position in Q3 2021.
Atara Biotherapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1802 holding.
140 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.